Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

Completed

Conditions studied: Acute Myeloid Leukemia

In brief

This study is designed to assess the safety of Mylotarg therapy in routine practice.

Key facts

Study ID

NCT00161668

Run by

Wyeth is now a wholly owned subsidiary of Pfizer

People needed

500

Starts

2001-10-01

Last updated by the study team

2007-03-15

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Treated by Mylotarg
• Provide ICF

Where it is running

• Study site — Berkely, California, United States
• Study site — Burbank, California, United States
• Study site — Concord, California, United States
• Study site — Loma Linda, California, United States
• Study site — Los Angeles, California, United States
• Study site — San Francisco, California, United States
• Study site — Sylmar, California, United States
• Study site — Denver, Colorado, United States
• Study site — Boynton Beach, Florida, United States
• Study site — Plantation, Florida, United States
• Study site — Stuart, Florida, United States
• Study site — Tamarac, Florida, United States
• Study site — Chicago, Illinois, United States
• Study site — Chicago, Illinois, United States
• Study site — Chicago, Illinois, United States
• Study site — Chicago, Illinois, United States
• Study site — Indianapolis, Indiana, United States
• Study site — Iowa City, Iowa, United States
• Study site — Lexington, Kentucky, United States
• Study site — Louisville, Kentucky, United States
• Study site — Shrevport, Louisiana, United States
• Study site — Ann Arbor, Michigan, United States
• Study site — Grand Rapids, Michigan, United States
• Study site — Kalamazoo, Michigan, United States
• Study site — Tucson, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.